Betahistine

Betahistine is a synthetic analog of histamine, classified pharmacologically as an anti-vertigo or antivertiginous agent ^[3]. It is most commonly supplied as betahistine dihydrochloride and is taken by mouth. Because its structure resembles the natural signaling molecule histamine, it interacts directly with histamine receptors, behaving as a weak partial agonist at the H1 receptor and a more potent antagonist at the H3 receptor ^[3][4].

The drug is prescribed chiefly for Meniere's disease, an inner-ear disorder marked by recurring attacks of vertigo, ringing in the ears (tinnitus), a sense of fullness in the ear, and fluctuating hearing loss ^[1]. It is used mainly to reduce the frequency and severity of vertigo episodes, particularly during the quieter phases between acute attacks, and it is also given for other forms of vertigo and balance disturbance ^[3]. Its effect on hearing loss and tinnitus is generally considered weak or unclear ^[3].

The evidence base for betahistine is mixed. A Cochrane systematic review found the available trials too small or methodologically limited to conclude whether the drug meaningfully affects Meniere's disease, while noting that it appeared well tolerated ^[1]. A later large, multicenter, placebo-controlled study known as the BEMED trial reported that betahistine did not reduce the rate of vertigo attacks any more than placebo over nine months ^[2]. Despite these inconclusive findings, expert consensus panels continue to recommend it during the intercritical phase of the disease to lessen the number and severity of attacks, citing its low risk of serious side effects ^[3]. Comparative studies have also weighed it against other anti-vertigo drugs such as cinnarizine ^[4].

Betahistine was introduced in the 1960s. In the United States it received Food and Drug Administration approval in 1966 on the strength of a single study, but that approval was withdrawn in 1972 after the agency judged the supporting evidence inadequate; as a result it is not marketed there and can be obtained only through compounding pharmacies ^[1]. In Europe it was first registered around 1970 and has since become a widely used treatment, and it is now approved in well over a hundred countries under brand names such as Serc ^[1]. It is generally dispensed as oral tablets.

The rationale for using betahistine rests on its ability to increase blood flow in the inner ear and to modulate histamine signaling in the vestibular system, which is thought to aid the natural process of vestibular compensation after balance is disturbed ^[3]. It is usually well tolerated, with mild gastrointestinal upset and headache among the more common complaints; because it is a histamine-like compound, caution is generally advised in people with asthma or a history of peptic ulcer ^[3].

Betahistine is generally well tolerated. The most common effects are headache, nausea and mild stomach upset. Because it is histaminergic, it should be used cautiously in people with active peptic ulcer disease or asthma, and it is not recommended in pheochromocytoma. It should not be combined with antihistamines, which act on the same receptors and can cancel its effect. It is not FDA approved in the United States, and the overall evidence for benefit is mixed, with some trials showing clear improvement in vertigo and others showing little difference from placebo.

Betahistine was first synthesized in the 1960s and introduced by the pharmaceutical company Unimed, reaching the market as an anti-vertigo agent under brand names such as Serc. Chemically a close analog of the neurotransmitter histamine, it was developed on the rationale that improving inner-ear blood flow could relieve the vertigo of Meniere's disease. Over the following decades it became one of the most widely prescribed vertigo treatments across Europe, Asia, and many other regions. It was voluntarily withdrawn from the United States market in the early 1970s after regulators concluded the evidence of efficacy at the time was insufficient, and it is not approved for general sale there, though it remains in broad use internationally.

Betahistine is one of the most familiar and widely prescribed treatments for Meniere's disease and vestibular vertigo across much of the world, valued by clinicians for its long track record and generally good tolerability. Patients often appreciate that, unlike some vestibular sedatives, it is not associated with heavy drowsiness and may support the brain's own process of vestibular compensation. Its dual action on the histamine system, mild H1 agonism paired with stronger H3 antagonism, keeps it of continuing scientific interest. In the spirit of honesty, it should be noted that controlled trials have produced mixed results and high-quality evidence remains limited, which is one reason it is used routinely in many countries yet is not approved in the United States.